Patient feedback changed the conversation on access for Botox in migraine care — watch how real-world insights reshaped value and future possibilities for innovative contracting.

Through the eyes of Omar Ali - a former NICE insider; a 30,000-foot full-throttle take on the collapse of NHS England's structure – and the ripple effects across commissioning, VPAG, NICE, ICBs and pharma's next move.

Performance-based agreements in China seemed impossible — until one deal showed what was possible. Watch how it built trust, access, and a path forward for markets worldwide.

Unlike cheap oral drugs, early PCSK9s were high-cost injections — and a tough sell. But one manufacturer used a VBA to secure trust and gain early access.

Watch the latest Verpora webinar on IRA Medicare drug price negotiations. Explore how CMS’s approach is shifting from IPAY 2026 to 2027, and what manufacturers should prepare for in IPAY 2028 and beyond. Access available by request.

Why do innovative contracts fail? Omar Ali and Adam Buckler explore real-world VBAs that didn’t launch—and what those failures teach us about doing it right.

How do you revive innovation in antibiotics? Explore the bold subscription models rewarding pharma for availability—not volume.

Oncology. Multiple indications. One bold move changed the pricing playbook. Watch how Roche did it.

Physician buy-in can make or break an innovative contract. In this episode, we explore real-world strategies to engage prescribers, overcome resistance, and drive adoption.

A bold performance-based contract looked like a win—until a key stakeholder pushed back. In this episode, we explore why stakeholder engagement is critical in Innovative Contracting. in cell and gene therapy.

How are payers responding when costly gene therapies don’t deliver long-term durability? We explore evolving contract models tackling buyer’s remorse in cell and gene therapy.

How a high-cost therapy’s contracts tackled access hurdles across the US, LATAM & Europe—outcome-based models, staged payments & service-linked discounts

In the debut episode of our new short video series: How a bold risk-sharing agreement transformed market access for an oncology treatment—challenging pricing norms and reshaping payer negotiations.

Verpora's webinar series exploring the latest trends and policies surrounding Global Innovative Contracting in January 2025, for US / LATAM Regions

Verpora's webinar series exploring the latest trends and policies surrounding Global Innovative Contracting in January 2025, for EU / UK / Asia Regions

Discover how evolving NHS data systems and payer priorities are reshaping market access. Verpora experts Omar Ali and Adam Buckler share actionable insights and real-world examples in this on-demand webinar.

A joint team of advisers from Verpora and Manatt Health share their unique approach to helping brands navigate IPAY 2026 negotiations, vital learnings from the process and critical recommendations for future negotiations.

The March 2024 edition of the latest in Verpora's webinar series exploring the latest trends and policies surrounding Global Innovative Contracting, for EU / UK / Asia Regions

The March 2024 edition of the latest in Verpora's webinar series exploring the latest trends and policies surrounding Global Innovative Contracting, for USA & LATAM Regions

South Korea has recently shown enthusiasm towards innovative contracting and risk-sharing agreements in healthcare, with the National Health Insurance Service actively discussing a more adaptive framework. A notable global influence in these discussions is the UK's NICE International institution, which is extending its reach beyond European markets, offering infrastructure capability development and sharing methodologies with countries like South Korea. As a result, South Korea is adapting and evolving its contracting models, particularly in oncology, to better fit its market while also benefiting from the expertise of international institutions like NICE.